Xilio Therapeutics (XLO) Accounts Payables (2020 - 2026)

Xilio Therapeutics has disclosed Accounts Payables across 7 years of filings, most recently posting $1.1 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $1.1 million, down 53.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 million (down 53.23% YoY), and the FY2025 annual result was $3.2 million, up 23.08% from the prior year.
• Accounts Payables came in at $1.1 million for Q1 2026 at Xilio Therapeutics, down from $3.2 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $4.1 million in Q2 2025 to a low of $746000.0 in Q1 2024.
• The 5-year median for Accounts Payables is $1.8 million (2022), against an average of $1.9 million.
• Across the five-year window, Accounts Payables sank 66.4% in 2023 and jumped 224.13% in 2025, its largest moves.
• Xilio Therapeutics' Accounts Payables stood at $3.1 million in 2022, then sank by 66.4% to $1.0 million in 2023, then soared by 145.14% to $2.6 million in 2024, then rose by 23.08% to $3.2 million in 2025, then plunged by 66.41% to $1.1 million in 2026.
• The last three Accounts Payables figures came in at $1.1 million (Q1 2026), $3.2 million (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.